


Hyrtimomines A–C, New Heteroaromatic
Alkaloids from a Sponge *Hyrtios* sp.Rei Momose,[†] Naonobu Tanaka,[†] Jane Fromont,[‡] and Jun'ichi Kobayashi^{*,†}

Graduate School of Pharmaceutical Sciences, Hokkaido University,
Sapporo 060-0812, Japan, and Western Australian Museum, Locked Bag 49,
Weishpool DC, WA 6986, Australia

jkobay@pharm.hokudai.ac.jp

Received March 14, 2013

ABSTRACT



Three new alkaloids, hyrtimomines A–C (1–3), were isolated from an Okinawan marine sponge *Hyrtios* sp. The structures of 1–3 were elucidated on the basis of spectroscopic analysis and application of a phenylglycine methyl ester (PGME) method. Hyrtimomines A (1) and B (2) are heteroaromatic alkaloids possessing a fused hexacyclic 6/5/6/6/7/5 ring system, while hyrtimomine C (3) is an alkaloid consisting of hydroxyindole and azepino-hydroxyindole moieties. Hyrtimomine A (1) exhibited cytotoxicity against KB and L1210 cells.

Marine sponges have been recognized as a rich source of bioactive secondary metabolites with fascinating chemical structures.¹ Among them, sponges belonging to the genus *Hyrtios* are known to be a source of heteroaromatic alkaloids with various structures.² Previously, we have reported the isolation of indole alkaloids, hyrtiosins A and B,³ gesashidine A,⁴ and hyrtinadine A⁵ from *Hyrtios* spp. We have also isolated

alkaloids having a furo[2,3-*b*]pyrazin-2(1*H*)-one moiety, hyrtioseragamines A and B, from *Hyrtios* sp.⁶ In our continuing search for structurally unique metabolites from Okinawan marine sponges, we investigated the extracts of *Hyrtios* sp. (SS-163) and isolated three new alkaloids, hyrtimomines A–C (1–3). In this Letter, we describe the isolation and structure elucidation of 1–3.

The sponge *Hyrtios* sp. (SS-163, 3.3 kg, wet weight) collected off Kerama Islands, Okinawa, was extracted with MeOH, and the extracts were partitioned between EtOAc and water. The EtOAc-soluble materials were partitioned between *n*-hexane and 10% MeOH aq., while the water layer was extracted with *n*-BuOH. Combined 10% MeOH aq.-soluble materials and *n*-BuOH-soluble materials were first fractionated by silica gel column chromatography, followed by fractionation by C₁₈ column chromatography. Next, fractions were further purified by MCI gel CHP-20P column chromatography, and final purification was achieved by C₁₈ HPLC or HILIC

[†] Hokkaido University.[‡] Western Australian Museum.(1) Blunt, J. W.; Copp, B. R.; Keyzers, R. A.; Munro, M. H. G.; Prinsep, M. R. *Nat. Prod. Rep.* **2013**, *30*, 237–323.(2) (a) Yamanokuchi, R.; Imada, K.; Miyazaki, M.; Kato, H.; Watanabe, T.; Fujimuro, M.; Saeiki, Y.; Yoshinaga, S.; Terasawa, H.; Iwasaki, N.; Rotinsulu, H.; Losung, F.; Mangindaan, R. E. P.; Namikoshi, M.; de Voogd, N. J.; Yokosawa, H.; Tsukamoto, S. *Bioorg. Med. Chem.* **2012**, *20*, 4437–4442. (b) Inman, W. D.; Bray, W. M.; Gassner, N. C.; Lokey, R. S.; Tenney, K.; Shen, Y. Y.; TenDyke, K.; Suh, T.; Crews, P. *J. Nat. Prod.* **2010**, *73*, 255–257. (c) Sauleau, P.; Martin, M.-T.; Dau, M.-E. T. H.; Youssef, D. T. A.; Bourguet-Kondracki, M.-L. *J. Nat. Prod.* **2006**, *69*, 1676–1679. (d) Youssef, D. T. A. *J. Nat. Prod.* **2005**, *68*, 1416–1419. (e) Aoki, S.; Ye, Y.; Higuchi, K.; Takashima, A.; Tanaka, Y.; Kitagawa, I.; Kobayashi, M. *Chem. Pharm. Bull.* **2001**, *49*, 1372–1374.(3) Kobayashi, J.; Murayama, T.; Ishibashi, M.; Kosuge, S.; Takamatsu, M.; Ohizumi, Y.; Kobayashi, H.; Ohta, T.; Nozoe, S.; Sasaki, T. *Tetrahedron* **1990**, *46*, 7699–7702.(4) Iinuma, Y.; Kozawa, S.; Ishiyama, H.; Tsuda, M.; Fukushima, E.; Kawabata, J.; Fromont, J.; Kobayashi, J. *J. Nat. Prod.* **2005**, *68*, 1109–1110.(5) Endo, T.; Tsuda, M.; Fromont, J.; Kobayashi, J. *J. Nat. Prod.* **2007**, *70*, 423–424.(6) Takahashi, Y.; Iinuma, Y.; Kubota, T.; Tsuda, M.; Sekiguchi, M.; Mikami, Y.; Fromont, J.; Kobayashi, J. *Org. Lett.* **2011**, *13*, 628–631.(7) Hyrtimomine A (1): dark-brown amorphous solid; UV (MeOH) λ_{max} 214 (ϵ 19 610), 293 (9680), 352 (7230 sh), 369 (9810), and 386 (8740) nm; IR (KBr) ν_{max} 3420, 1740–1640 (br), and 1200 cm^{-1} ; ¹H and ¹³C NMR (Table 1); HRESIMS: m/z 314.09221 [$M + H$]⁺ (calcd for C₁₉H₁₂N₃O₂, 314.09240).

HPLC to afford hyrtimomines A (**1**, 0.00009%, wet weight), B (**2**, 0.00023%), and C (**3**, 0.00012%).

Hyrtimomine A (**1**)⁷ was obtained as a dark-brown amorphous solid. The UV spectrum suggested the presence of a conjugated aromatic chromophore. The molecular formula of **1**, C₁₉H₁₁N₃O₂, was established by the HRESIMS (m/z 314.09221 [$M + H$]⁺, Δ -0.19 mmu), corresponding to 16 degrees of unsaturation. The ¹H NMR spectrum showed signals of three D₂O-exchangeable, six aromatic, and two olefinic protons, while the ¹³C NMR spectrum displayed the resonances of 17 aromatic and two olefinic carbons (Table 1). From these data, **1** was elucidated to be a heteroaromatic alkaloid with a highly condensed structure.

The structures of two partial units (units A and B) in **1** were assigned as follows. In unit A (N-1, C-2–C-9, and N-10), the presence of a 3,4-disubstituted-5-hydroxyindole moiety was suggested by analysis of the ¹H–¹H COSY and HMBC spectra (Figure 1). ¹H–¹H COSY cross-peaks of H-8/H-9 and H-9/10-NH and HMBC correlations for H-8/C-2, H-8/C-3a, and H-9/C-3 disclosed that an ethenamine moiety (C-8 and C-9) was connected to C-3. The geometry of the olefin was assigned as *Z* based on the coupling constant for H-8/H-9 ($J = 9.5$ Hz). Similarly, the structure of a 2,3-disubstituted-5-hydroxyindole moiety (unit B, N-1'–C-7'a) was deduced. The presence of an oxygen attached to C-2' was implied by the chemical shift of C-2' (δ_C 157.0). Thus, the structures of units A and B were assigned as shown in Figure 1.




Figure 1. Selected 2D NMR correlations for units A and B in hyrtimomine A (**1**).

In addition to the 2D NMR correlations shown in Figure 1, an HMBC correlation for H-9 to an sp² quaternary carbon (δ_C 152.3, C-8') was observed, suggesting the connectivity of C-9 to C-8' via N-10. Given the degree of unsaturation of **1** and a ROESY cross-peak of 10-NH/H-4', the structure of hyrtimomine A (**1**) was elucidated as shown in Figure 2.




Figure 2. Structure and key 2D NMR correlations of hyrtimomine A (**1**).

Hyrtimomine B (**2**)⁸ was obtained as an optically active yellow amorphous solid [$[\alpha]_D^{22} -276.8$ (c 0.027, MeOH)]. The HRESIMS revealed the molecular formula of **2** to be C₂₀H₁₃N₃O₄ (m/z 360.09789 [$M + H$]⁺, Δ +0.01 mmu). The ¹H and ¹³C NMR spectra of **2** were similar to those of **1**, and the signals due to one nitrogen bearing an sp³ methine (CH-9), one sp³ methylene (CH₂-8), and one carboxy group (C-11) in **2** were discerned in place of the resonances of the *Z*-olefine (CH-8 and CH-9) in **1** (Table 1). The connectivity of C-8 to N-10 via C-9 was confirmed by ¹H–¹H COSY cross-peaks of H₂-8/H-9 and H-9/10-NH, implying that the carboxy group (C-10) was attached to C-9 (Figure 3). Thus, the gross structure of hyrtimomine B (**2**) was elucidated as shown in Figure 3.




Figure 3. Selected 2D NMR correlations for hyrtimomine B (**2**).

To assign the absolute configuration at C-9, hyrtimomine B (**2**) was converted into the (*S*)- and (*R*)-PGME (PGME = phenylglycine methyl ester) amides (**2a** and **2b**, respectively). The $\Delta\delta$ values ($\Delta\delta = \delta_S - \delta_R$) obtained from the ¹H NMR data for **2a** and **2b** indicated the absolute configuration of C-9 in **2** to be *S* (Figure 4).⁹

Hyrtimomine C (**3**)¹⁰ was isolated as a yellow amorphous solid. The HRESIMS indicated the molecular formula of **3** to be C₁₉H₁₃N₃O₃ (m/z 332.10288 [$M + H$]⁺, Δ -0.11 mmu).

(8) Hyrtimomine B (**2**): yellow amorphous solid; [$[\alpha]_D^{22} -276.8$ (c 0.027, MeOH)]; UV (MeOH) λ_{\max} 219 (ϵ 11 780), 243 (6480 sh), 290 (5490), 327 (2750 sh), 343 (2980 sh), and 389 (4930) nm; IR (KBr) ν_{\max} 3383, 1645, 1592, 1572, and 1364 cm⁻¹; ¹H and ¹³C NMR (Table 1); HRESIMS: m/z 360.09789 [$M + H$]⁺ (calcd for C₂₀H₁₄N₃O₄, 360.09788).


(9) Yabuuchi, T.; Kusumi, T. *J. Org. Chem.* **2000**, *65*, 397–404.

(10) Hyrtimomine C (**3**): yellow amorphous solid; UV (MeOH) λ_{\max} 215 (ϵ 24 980), 272 (7430), 295 (7360), 380 (6680), and 474 (3720) nm; IR (KBr) ν_{\max} 3427, 2926, 1733–1604 (br), 1588, 1205, and 1138 cm⁻¹; ¹H and ¹³C NMR (Table 1); HRESIMS: m/z 332.10288 [$M + H$]⁺ (calcd for C₁₉H₁₄N₃O₃, 332.10297).

Table 1. ^1H and ^{13}C NMR Data for Hyrtimomines A–C (**1–3**) in $\text{DMSO-}d_6$


| position | 1 | | 2 | | 3 | |
|----------|-----------------|---------------------------------|--------------------|---|-----------------|-------------------------------------|
| | ^{13}C | ^1H | ^{13}C | ^1H | ^{13}C | ^1H |
| 1 | — | 11.40 (1H, brs) | — | 12.00 (1H, brs) | — | 13.15 (1H, brs) |
| 2 | 125.2 | 6.97 (1H, brs) | 126.3 | 7.67 (1H, brs) | 134.3 | 8.38 (1H, s) |
| 3 | 115.0 | — | 114.2 | — | 118.0 | — |
| 3a | 125.7 | — | 122.6 | — | 127.1 | — |
| 4 | 108.7 | — | 106.2 | — | 107.1 | — |
| 5 | 146.1 | — | 148.7 | — | 161.4 | — |
| 6 | 113.1 | 7.10 (1H, d, $J = 8.8$ Hz) | 110.9 | 7.57 (1H, d, $J = 8.6$ Hz) | 113.9 | 7.03 (1H, d, $J = 8.6$ Hz) |
| 7 | 119.7 | 7.43 (1H, d, $J = 8.8$ Hz) | 119.5 | 7.99 (1H, d, $J = 8.6$ Hz) | 123.7 | 7.99 (1H, d, $J = 8.6$ Hz) |
| 7a | 134.9 | — | 132.6 | — | 130.2 | — |
| 8 | 110.9 | 5.39 (1H, d, $J = 9.5$ Hz) | 30.4 | 3.63, 3.48 (1H each, brs) ^a | 183.9 | — |
| 9 | 121.9 | 5.55 (1H, brd, $J = 9.5$ Hz) | 58.7 | 5.20 (1H, brs) | 56.9 | 4.25 (2H, m) |
| 10 | — | 8.27 (1H, brs) | — | 8.97 (1H, brs) | — | — |
| 11 | — | — | 170.7 | 13.78 (1H, brs) | — | — |
| 1' | — | — | — | — | — | 12.40 (1H, brs) |
| 2' | 157.0 | — | 154.7 ^b | — | 135.0 | 8.04 (1H, brs) |
| 3' | 95.8 | — | 94.3 | — | 110.2 | — |
| 3'a | 119.7 | — | 120.4 | — | 126.5 | — |
| 4' | 108.1 | 7.87 (1H, s) | 106.2 | 7.77 (1H, brs) | 103.4 | 6.43 (1H, brs) |
| 5' | 154.0 | — | 153.7 | — | 153.4 | — |
| 6' | 114.8 | 6.94 (1H, d, $J = 8.6$ Hz) | 114.2 | 6.99 (1H, brd, $J = 7.9$ Hz) | 113.4 | 6.72 (1H, dd, $J = 8.6, 1.9$ Hz) |
| 7' | 113.5 | 7.32 (1H, d, $J = 8.6$ Hz) | 113.7 | 7.45 (1H, d, $J = 7.9$ Hz) | 113.4 | 7.41 (1H, d, $J = 8.6$ Hz) |
| 7'a | 127.9 | — | 127.5 | — | 131.3 | — |
| 8' | 152.3 | — | 157.9 ^b | — | 166.1 | — |
| 5-OH | — | — | — | — | — | 11.18 (1H, brs) |
| 5'-OH | — | 9.67 (1H, brs) | — | 9.66 (1H, brs) | — | 9.12 (1H, brs) |

^a Signals were overlapped with that of HOD. ^b Signals may be interchangeable.

**Figure 4.** $\Delta\delta$ values [$\Delta\delta$ (in ppm) = $\delta_S - \delta_R$] obtained for the (S)- and (R)-PGME amides (**2a** and **2b**) of hyrtimoimine B (**2**).


The ^1H and ^{13}C NMR spectra revealed the presence of one ketone carbonyl group, one sp^2 quaternary carbon, and one sp^3 methylene adjacent to a nitrogen atom as well as two 5-hydroxyindole moieties (Table 1).

The structures of 3,4-disubstituted-5-hydroxyindole (N-1–C-7a) and 3-monosubstituted-5-hydroxyindole (C-1'–C-7'a)

**Figure 5.** Selected 2D NMR correlations for hyrtimoimine C (**3**).

moieties in **3** were confirmed by analysis of the 2D NMR spectra measured in $\text{DMSO-}d_6$, whereas no correlation suggesting the connectivity of CH_2 -9 to the other atoms was observed because of its broadening proton signal. On the other hand, the ^1H NMR spectrum measured in CD_3OD gave the sharp resonance of H_2 -9 [δ_{H} 4.38 (2H, s)]. In the HMBC spectrum in CD_3OD , correlations for H_2 -9 to C-3, C-8, and C-8' were observed (Figure 5), indicating the connectivities of C-3 to the sp^2 methylene (C-9) through a

Scheme 1. Possible Biogenetic Path of Hyrtimomines A–C (1–3)



ketone carbonyl group (C-8) and of C-9 to an sp^2 quaternary carbon (C-8') through a nitrogen atom (N-10). In addition, the connectivities among N-10, C-3', and C-4 via C-8' were disclosed by an HMBC cross-peak of H-2'/C-8' and a 4J HMBC correlation for H-6/C-8'. Therefore, the structure of hyrtimomine C was elucidated to be 3.

Hyrtimomines A (1) and B (2) are structurally unique heteroaromatic alkaloids with a fused hexacyclic 6/5/6/6/7/5

ring system. Hyrtimomine C (3) is an alkaloid consisting of a hydroxyindole and azepino-hydroxyindole moieties. These alkaloids have an azepino-indole moiety in common, while some azepino-indole alkaloids, hyrtiazepine,^{2c} hyrtioreticulins C and D,^{2a} and clavicipitic acid,¹¹ have been reported to date.

A possible biogenetic path of hyrtimomines A–C (1–3) from hyrtiazepine is proposed as shown in Scheme 1. Hyrtiazepine seems to be derived from 5-hydroxy-L-tryptophan and 5-hydroxyindole-3-aldehyde.³ Decarboxylation and oxidation of hyrtiazepine might give hyrtimomine C (3). Hyrtimomine B (2) might be derived by intramolecular cyclization of hyrtiazepine and followed by decarboxylation to generate hyrtimomine A (1). Although the absolute stereochemistry of hyrtiazepine has not been reported,^{2c} the absolute configuration of C-9 in hyrtimomine B (2) was coincident with that of 5-hydroxy-L-tryptophan.

Hyrtimomine A (1) showed cytotoxicity against human epidermoid carcinoma KB cells (IC_{50} 3.1 $\mu\text{g/mL}$) and muline leukemia L1210 cells (IC_{50} 4.2 $\mu\text{g/mL}$) *in vitro*, while hyrtimomines B (2) and C (3) did not show such cytotoxicity ($IC_{50} > 10 \mu\text{g/mL}$).

Acknowledgment. We thank S. Oka and A. Tokumitsu, Equipment Management Center, Hokkaido University, for measurements of MS spectra, and Z. Nagahama for his help with sponge collection. This work was partly supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Supporting Information Available. Experimental section, 1D and 2D NMR spectra of hyrtimomines A–C and the derivatives of hyrtimomine B. This material is available free of charge via the Internet at <http://pubs.acs.org>.

(11) Robbers, J. E.; Otsuka, H.; Floss, H. G.; Arnold, E. V.; Clardy, J. *J. Org. Chem.* **1980**, *45*, 1117–1121.

The authors declare no competing financial interest.